ECSP24002381A - Proteínas actrii y usos de las mismas - Google Patents

Proteínas actrii y usos de las mismas

Info

Publication number
ECSP24002381A
ECSP24002381A ECSENADI20242381A ECDI202402381A ECSP24002381A EC SP24002381 A ECSP24002381 A EC SP24002381A EC SENADI20242381 A ECSENADI20242381 A EC SENADI20242381A EC DI202402381 A ECDI202402381 A EC DI202402381A EC SP24002381 A ECSP24002381 A EC SP24002381A
Authority
EC
Ecuador
Prior art keywords
pulmonary
lung disease
disease
hypertension associated
pulmonary hypertension
Prior art date
Application number
ECSENADI20242381A
Other languages
English (en)
Inventor
Patrick Andre
Ravindra Kumar
Gang Li
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of ECSP24002381A publication Critical patent/ECSP24002381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En algunos aspectos, la divulgación se refiere a composiciones y métodos que comprenden polipéptidos de ActRII para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de la hipertensión pulmonar asociada con la enfermedad pulmonar (p. ej., la hipertensión pulmonar asociada con la enfermedad pulmonar obstructiva crónica (EPOC), la enfermedad pulmonar intersticial (EPI) o la combinación de fibrosis pulmonar y enfisema (CFPE)), en particular para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de una o más complicaciones asociadas con hipertensiones pulmonares asociadas con la enfermedad pulmonar (p. ej., la hipertensión pulmonar asociada con la enfermedad pulmonar obstructiva crónica (EPOC), la enfermedad pulmonar intersticial (EPI) o la combinación de fibrosis pulmonar y enfisema (CFPE)).
ECSENADI20242381A 2021-06-11 2024-01-11 Proteínas actrii y usos de las mismas ECSP24002381A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163209871P 2021-06-11 2021-06-11

Publications (1)

Publication Number Publication Date
ECSP24002381A true ECSP24002381A (es) 2024-02-29

Family

ID=84426426

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20242381A ECSP24002381A (es) 2021-06-11 2024-01-11 Proteínas actrii y usos de las mismas

Country Status (18)

Country Link
US (1) US20240277806A1 (es)
EP (1) EP4351626A4 (es)
JP (1) JP2024521575A (es)
KR (1) KR20240035445A (es)
CN (1) CN117794562A (es)
AU (1) AU2022289885A1 (es)
CA (1) CA3221581A1 (es)
CL (1) CL2023003659A1 (es)
CO (1) CO2024000079A2 (es)
CR (1) CR20240013A (es)
DO (1) DOP2023000269A (es)
EC (1) ECSP24002381A (es)
GE (1) GEAP202416434A (es)
IL (1) IL309100A (es)
JO (1) JOP20230321A1 (es)
MX (1) MX2023014761A (es)
PE (1) PE20242364A1 (es)
WO (1) WO2022261436A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284392A (zh) * 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
DK3496739T3 (da) * 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
KR20250133994A (ko) * 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
WO2021092079A1 (en) * 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis

Also Published As

Publication number Publication date
CN117794562A (zh) 2024-03-29
CA3221581A1 (en) 2022-12-15
GEAP202416434A (en) 2024-04-25
DOP2023000269A (es) 2024-04-30
AU2022289885A1 (en) 2024-01-18
JP2024521575A (ja) 2024-06-03
MX2023014761A (es) 2024-01-19
CL2023003659A1 (es) 2024-06-28
EP4351626A2 (en) 2024-04-17
IL309100A (en) 2024-02-01
WO2022261436A3 (en) 2023-01-19
JOP20230321A1 (ar) 2023-12-11
PE20242364A1 (es) 2024-12-16
CR20240013A (es) 2024-04-01
WO2022261436A2 (en) 2022-12-15
EP4351626A4 (en) 2025-04-16
CO2024000079A2 (es) 2024-01-25
US20240277806A1 (en) 2024-08-22
KR20240035445A (ko) 2024-03-15

Similar Documents

Publication Publication Date Title
ECSP23004827A (es) Proteínas actrii para el tratamiento de la hipertensión pulmonar
CO2022016210A2 (es) Proteínas actrii y su uso en el tratamiento de la hipertensión pulmonar postcapilar
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
DK1283735T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
ECSP24002381A (es) Proteínas actrii y usos de las mismas
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
WO2009011782A3 (en) METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
CL2011003273A1 (es) Antígeno del virus respiratorio sincicial (vrs) recombinante, que comprende un polipéptido de proteína f soluble con una modificación que altera su glicosilación y que a su vez comprende un dominio f1 y un dominio f2 de proteína f de vrs; composición inmunogénica que lo comprende; ácido nucleico que lo codifica; vector; célula hospedera; método para producir dicho antígeno del vrs; y su uso para tratar una infección de vrs.
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
NO20084187L (no) Medikamenter og proteiner
GEP20125531B (en) Reconstituted surfactants having improved properties
MX336384B (es) Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal.
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
EA201990514A1 (ru) Комбинированная терапия для хобл
PE20230090A1 (es) Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos
BRPI0510167A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar
WO2022192420A3 (en) Actrii proteins and uses thereof
NO20080434L (no) Luftveisadministrering av vevsfaktor veiinhibitorer i inflammatoriske tilstander som pavirker luftveien
WO2021231803A3 (en) Binding molecules for covid-19 treatment
JOP20240233A1 (ar) بروتينات cd24 الطافرة واستخداماتها للوقاية من السرطان وعلاجه
WO2006105279A3 (en) Defective sindbis viral vectors
BR112022003226A2 (pt) Uso de um inibidor de elastase de neutrófilos em doença pulmonar